India Animal Health and Veterinary Care Market Size, Share & Forecast, By Product Type, Animal Type & Care Setting, 2026–2031

The India Animal Health and Veterinary Care Market was valued at USD 2.29 billion in 2025. The estimate covers veterinary pharmaceuticals, vaccines and biologics, diagnostics, relevant nutraceuticals and medicinal feed additives, and paid veterinary-care services delivered within India. Production animals account for the largest demand pool because of the country’s dairy, poultry and livestock scale, while companion-animal services and diagnostics provide faster-growing, higher-value revenue. The base-year estimate is anchored to the published USD 2.1 billion 2024 market level and adjusted for 2025 operating growth.

The market is projected to reach USD 3.91 billion by 2031, expanding at a 9.33% CAGR during 2026-2031. Growth should be supported by preventive biologics, national disease-control programs, organized clinics, molecular diagnostics, point-of-care testing and higher companion-animal expenditure. Annual growth is modeled to increase from 8.8% in 2026 to 10.0% in 2031 as technology-led categories form a larger revenue mix. The forecast assumes continuity in vaccination programs, improving formal channel penetration and no prolonged disruption to veterinary pharmaceutical or biologics supply.

Incremental profit pools will move toward preventive biologics, molecular and point-of-care diagnostics, companion-animal specialty care and integrated farm-health services. Conventional therapeutic products will remain essential but face stronger generic competition and procurement pressure. Diagnostics and specialty services benefit from higher clinical differentiation, recurring testing and lower direct exposure to tender pricing. Digital follow-up, remote triage and connected herd management can also improve practitioner productivity and customer retention. By 2031, the modeled digital and point-of-care revenue mix reaches 27%, compared with 11% in 2025.

The principal structural constraint is insufficient and uneven veterinary-service capacity. India had approximately 87,914 registered veterinarians against a livestock population of about 53.7 crore animals, implying roughly 6,108 livestock animals per veterinarian. Infrastructure is also tiered: only 13,173 of 67,889 veterinary institutions are hospitals or polyclinics, while the remainder are dispensaries and aid centres with variable diagnostic and procedural capability. The result is lower preventive coverage, delayed referral and uneven product adoption, particularly in rural livestock markets.

India ranks second among the selected peer markets by 2025 revenue, behind China but ahead of Thailand, Indonesia, Pakistan and Bangladesh. India’s modeled USD 2.29 billion market is smaller than China’s USD 2.96 billion market, but India’s 9.33% forecast CAGR is higher than China’s 7.29% and Indonesia’s 4.10%. India’s advantage comes from its livestock scale, domestic pharmaceutical base and public disease-control programs; its disadvantage is lower service access and greater fragmentation across rural care settings.

The most important demand driver is the economic value attached to livestock productivity. India’s approximately 536.76 million livestock animals support dairy, poultry, meat and rural-income value chains, while milk production reached about 239.3 million tonnes in 2023-24. Disease prevention, reproductive care and nutrition-linked therapeutics directly protect output and farmer cash flow. Public vaccination programs reinforce this commercial logic by creating population-scale coverage, while export requirements increase demand for traceability, residue control and disease certification.

The competitive landscape includes multinational animal-health companies and Indian vaccine and pharmaceutical manufacturers. Leading participants profiled in this report are Zoetis India Limited, MSD Animal Health India, Boehringer Ingelheim India, Elanco India Private Limited, Virbac Animal Health India Private Limited, Ceva Animal Health India, Indian Immunologicals Limited, Hester Biosciences Limited, Intas Animal Health and Vetoquinol India Animal Health Private Limited. Competitive advantage depends on portfolio breadth, vaccine capacity, India-specific clinical evidence, institutional procurement access, distribution reach and veterinarian engagement.